Canakinumab

Anti-IL-1β monoclonal antibody

Response rate
45% complete (Phase III); >94% disease control (long-term)
Onset
Days–weeks
Route
SC 150mg every 4–8 weeks
Line
1st
IgM effect
N/A

Evidence summary

Selectively neutralises IL-1β with a long half-life allowing monthly dosing. The CLUSTER Phase III RCT (De Benedetti 2018) showed 45% complete response vs 8% placebo in TRAPS. The 72-week extension demonstrated >94% achieving no/minimal disease activity with sustained treatment. FDA/EMA approved for TRAPS. No patients on canakinumab developed AA amyloidosis in the Eurofever registry.

Molecular targets (1)

MoleculeRoleExpressionEvidence
IL-1βKey effector cytokineElevatedestablished

Sources (4)

DetailsDe Benedetti F et al. (2018) Canakinumab for the treatment of autoinflammatory recurrent fever syndromes · N Engl J MedDOI ↗
DetailsGattorno M et al. (2024) Long-term efficacy and safety of canakinumab in patients with TRAPS: results from a phase III trial · Arthritis RheumatolDOI ↗
DetailsGattorno M et al. (2017) Canakinumab treatment for patients with active recurrent or chronic TRAPS: an open-label, phase II study · Ann Rheum DisDOI ↗
DetailsPapa R et al. (2021) INSAID variant classification and Eurofever criteria guide optimal treatment strategy in patients with TRAPS: data from the Eurofever Registry · J Allergy Clin Immunol PractDOI ↗